FDA Grants Fast Track Designation to Omeros’ OMS824 Huntington’s Disease Program
FDA Grants Fast Track Designation to Omeros’ OMS824 Huntington’s Disease Program — Enrollment in Huntington’s Phase 2 Trial Expected Soon — PR Newswire SEATTLE, Feb. 5, 2014 SEATTLE , Feb. 5, 2014 /PRNewswire/ — Omeros Corporation (NASDAQ: OMER) today announced that the U.S. […]